Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide affecting over 600,000 people yearly.
Patients with chronic liver diseases (NASH, HCV, HBV) and cirrhosis are strongly predisposed to the development of HCC. It is expected that HCC will continue to grow in the upcoming years, urging the development of new efficient care for patients.
EASL acknowledges the importance of clinical and translational research in this field and has planned to host an HCC summit
entirely dedicated to this topic in February 2017, Geneva.
In addition, the State of the Art lectures
at ILC 2017, Amsterdam, will be given by world-class specialists and scientists; Profs. Mike N. Hall and Vincenzo Mazzaferro who will deliver the latest on HCC research and patient management.
Discover future EASL events on HCC
The EASL HCC Summit
will take place 2-5 February 2017 in Geneva, Switzerland.
This conference combines both the basic science and clinical science aspects of liver cancer.
Basic Science sessions will cover:
Next generation and exome sequencing, Molecular signaling and imaging, Angiogenesis, Cell metabolism, Cell death, Inflammation, Gut microbiome, Genomic instability.
Clinical sessions will include:
Patient management, Epidemiology, Diagnostic challenges, Surgical and locoregional therapy, Intrahepatic cholangiocarcinoma, Systemic Treatments, Immunotherapy.
Discover the scientific programme
and the list of invited speakers and chairs
Submit your abstract.
Deadline 28 November 2016!
100 EASL bursaries on offer for young investigators and trainees!
EASL offers 2 types of bursaries to the presenting authors of the best-accepted abstracts.
Up to 50 full bursaries of 650.00€ each and 50 registration bursaries are on offer.
The International Liver CongressTM 2017 website is now live!
Discover the online programme and mark your calendar for 2017.
See you in Amsterdam.
The EASL Office